The Anglo-German biotechnology company, Cellzome, has delivered a candidate small molecule drug to GlaxoSmithKline Plc for development against an undisclosed kinase target in the area of inflammatory disease, the first of two new milestones. ---Subscribe to MedNous to access this article--- Company News
